Abstract 1877
Background
Based on mRNA expression, accRCC can be divided in four molecular subtypes (ccrcc1-4), associated with prognosis, angiogenic signature, immune phenotype and therapy response. miRNAs are master regulators of mRNA function. We assessed the correlation of miRNA expression with (1) ccrccc1-4 subtypes, (2) mRNA targets and (3) outcome.
Methods
We performed miRNome analysis of 128 accRCC. (1) Unsupervised hierarchical clustering was done using 50 miRNAs with the most variable expression across all samples. Results were validated on TCGA data (n = 255). (2) For miRNAs with subtype-specific expression, we performed pathway analysis of predicted mRNA targets (IPA, KEGG) and assessed target-downregulation in TCGA. (3) We used Cox regression to correlate miRNA expression with overall survival (OS) since diagnosis. Hazard ratios (HR) were correlated with subtype-specific expression (Pearson).
Results
(1) Samples separated in two miRNA clusters, that partially overlapped with molecular subtypes. Cluster 1 consisted of 69% favourable subtypes (ccrcc2 or 3), cluster 2 of 77% unfavourable (ccrcc1 or 4) (p < 2.2e-16). (2) Pathway analysis of predicted mRNA targets and targets suppressed in TCGA, suggested that favourable subtypes exhibit more angiogenic signaling, whereas unfavourable subtypes activate pathways involved in tumor invasiveness. (3) Several miRNAs were significantly associated with OS. There was a robust correlation in the entire dataset between HR for OS and differential expression between favourable/unfavourable subtypes (r = 0.322; p < 0.0001).Table:
973P
miRNA | Subtype-specific expression log2FoldChange <0: higher in ccrcc1 or -4 (unfavourable) log2FoldChange >0: higher in ccrcc2 or -3 (favourable) | *p<0.05 ** false discovery rate <0.05 | Overall survival (hazard ratio) | |
---|---|---|---|---|
182-5p | -1,43 | ** | 1,25 | ** |
3529-3p | -1,42 | ** | 1,37 | ** |
335-3p | -1,33 | ** | 1,25 | ** |
34c-5p | -1,22 | ** | 1,25 | ** |
193b-3p | -1,17 | ** | 1,31 | ** |
370-3p | -1,07 | ** | 1,16 | ** |
199b-5p | -1,05 | ** | 1,26 | ** |
21-3p | -0,89 | ** | 1,47 | ** |
574-5p | -0,89 | ** | 1,40 | ** |
4792 | -0,88 | ** | 0,88 | * |
let-7i-5p | -0,81 | ** | 1,66 | ** |
652-3p | -0,75 | ** | 1,39 | ** |
1301-3p | -0,70 | ** | 1,39 | ** |
222-3p | -0,66 | ** | 1,31 | * |
320a | -0,63 | ** | 1,28 | ** |
425-5p | -0,62 | ** | 1,66 | ** |
149-5p | -0,61 | ** | 1,32 | * |
146b-5p | -0,54 | * | 1,49 | ** |
193b-5p | -0,49 | 1,21 | ** | |
185-5p | -0,49 | ** | 1,42 | ** |
21-5p | -0,42 | * | 1,68 | ** |
7641 | -0,33 | 0,80 | ** | |
320b | -0,28 | 1,25 | ** | |
1260b | -0,15 | 0,79 | ** | |
4454 | 0,15 | 0,80 | ** | |
6880-5p | 0,25 | 0,64 | ** | |
27b-3p | 0,36 | ** | 0,71 | * |
1260a | 0,38 | 0,73 | ** | |
7977 | 0,39 | 0,73 | ** | |
23b-3p | 0,48 | ** | 0,81 | ** |
2392 | 0,55 | 0,80 | ** | |
194-5p | 0,55 | * | 0,74 | ** |
30c-5p | 0,70 | ** | 0,78 | * |
190a-5p | 0,86 | ** | 0,83 | ** |
204-5p | 1,23 | ** | 0,71 | ** |
135a-5p | 1,37 | ** | 0,86 | ** |
Conclusions
accRCC molecular subtypes exhibit different miRNA expression patterns. Differentially expressed miRNAs are implicated in pathways driving tumor biology and strongly correlated with OS. These findings underscore the robustness of the molecular subtypes and are, to the best of our knowledge, the first to show an association of global miRNome expression with outcome.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Fonds Wetenschappelijk Onderzoek Vlaanderen.
Disclosure
M. Albersen: Research grant / Funding (self): Ipsen. B. Beuselinck: Advisory / Consultancy, Research grant / Funding (self): Bristol Meyers Squibb; Speaker Bureau / Expert testimony: Ipsen; Speaker Bureau / Expert testimony: Merck; Research grant / Funding (self): Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
5822 - Greek nursing students experience facing death in clinical practice
Presenter: Maria Dimoula
Session: Poster Display session 3
Resources:
Abstract
2866 - HOPEVOL: Hospice care appropriate to the wishes and needs of patients in the palliative terminal phase.
Presenter: Merel van Klinken
Session: Poster Display session 3
Resources:
Abstract
829 - Mindfulness-based stress reduction in early palliative care for advanced cancer patients : an italian single-centre study. MINDEEP
Presenter: Emilia Gianotti
Session: Poster Display session 3
Resources:
Abstract
2702 - Optimising Inpatient Oncology Care
Presenter: Lisa Judge
Session: Poster Display session 3
Resources:
Abstract
1527 - Analysis on the Implementation Results of Family Sickbed for Oncology Patients in Dongshi Township Health Centers from 2015 to 2017
Presenter: Yayu Huang
Session: Poster Display session 3
Resources:
Abstract
2054 - Exploring needs for palliative care and quality of life for oncology patients with advanced disease who undergo radiotherapy
Presenter: Foteini Antonopoulou
Session: Poster Display session 3
Resources:
Abstract
5605 - Cytotoxic contamination in cancer care settings – Risks and safety awareness among cancer nurses
Presenter: Sandra Lundman Vikberg
Session: Poster Display session 3
Resources:
Abstract
5769 - Understanding Chemotherapy - group education sessions prior to commencing chemotherapy
Presenter: Aileen McHale
Session: Poster Display session 3
Resources:
Abstract
2620 - Estimation of HPQ-based absenteeism and presenteeism in cancer patients via ResearchKit
Presenter: Shunsuke Kondo
Session: Poster Display session 3
Resources:
Abstract
4705 - Identifying falls-related variables and risk factors in hospitalised cancer patients
Presenter: Maria Montserrat Martí Dillet
Session: Poster Display session 3
Resources:
Abstract